var data={"title":"Cefotetan: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefotetan: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5841?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefotetan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefotetan: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cefotetan-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefotetan: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46216290\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cefotan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147623\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cephalosporin (Second Generation)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147596\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible infections:</b> IM, IV: Usual dose: 1 to 2 g every 12 hours; for life-threatening infections use 3 g IV every 12 hours (maximum dose/day: 6 g; for IM use, manufacturer&rsquo;s labeling includes a maximum dose of up to 4 g/day); <b>Note:</b> Due to high rates of <i>B. fragilis</i> group resistance, not recommended for the treatment of community-acquired intra-abdominal infections (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease:</b> IV: 2 g every 12 hours in combination with doxycycline oral or IV; transition from parenteral to oral therapy using doxycycline can usually be initiated within 24 to 48 hours of clinical improvement for a total treatment duration of 14 days. If tubo-ovarian abscess is present, oral clindamycin or oral metronidazole in combination with doxycycline is preferred to complete at least 14 days of therapy (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate: <b>Note:</b> <i>K. pneumoniae</i> infections should be treated with 1 or 2 g IV or IM every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 1 g every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 2 g every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe: IV: 2 g every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> IV: 1 to 2 g 30 to 60 minutes prior to surgery. <b>Note:</b> When used for cesarean section, dose should be given as soon as umbilical cord is clamped.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendations:</i> IV: 2 g within 60 minutes prior to surgery. Doses may be repeated in 6 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection:</b> IM, IV: 500 mg every 12 hours or 1 to 2 g every 12 to 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147614\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cefotetan-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefotetan: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible infection</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate infection: 30 mg/kg/dose every 12 hours (maximum dose: 4,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe infection: 50 mg/kg/dose every 12 hours (usual maximum dose: 4,000 mg/day; for life-threatening infections doses as high as 3,000 mg every 12 hours [6,000 mg/day] have been used)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection, complicated (off-label use):</b> Children and Adolescents: IV: 20 to 40 mg/kg/dose every 12 hours. <b>Note:</b> Due to high rates of <i>B. fragilis</i> group resistance, not recommended for the treatment of community-acquired intra-abdominal infections (IDSA [Solomkin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis (off-label use):</b> Children &ge;1 year: IV: 40 mg/kg/dose 30 to 60 minutes prior to surgery (maximum: 2,000 mg/dose). Doses may be repeated in 6 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147597\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147598\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer&rsquo;s labeling: </i>\n      <b>Note: </b> Renal function estimated using the Cockcroft-Gault formula:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 30 mL/minute: Administer usual dose every 24 hours <b>or</b> 50% of the usual dose administered every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer usual dose every 48 hours <b>or</b> 25% of the usual dose administered every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) on intermittent hemodialysis: Dialyzable (5% to 20%); administer 25% the usual dose every 24 hours on days between dialysis; administer 50% the usual dose on the day of dialysis (administer after dialysis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Alternate recommendations: </i>\n      <b>Note:</b> Renally adjusted dose recommendations are based on a dose of 1 to 2 g every 12 hours (Aronoff 2007):</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer every 24 hours.</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer every 48 hours.</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">Peritoneal dialysis: 1 g every 24 hours</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">Continuous renal replacement therapy: Administer every 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682538\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147571\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cefotan: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147555\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147575\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Inject deep IM into large muscle mass.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Inject via direct IV over 3 to 5 minutes. Infuse via intermittent infusion over 30 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147574\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone and joint infections: </b>Treatment of bone and joint infections caused by <i>Staphylococcus aureus</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gynecologic infections: </b>Treatment of gynecologic infections caused by <i>S. aureus</i>, (including penicillinase- and non-penicillinase-producing strains), <i>Staphylococcus epidermidis</i>, <i>Streptococcus</i> spp. (excluding enterococci), <i>Streptococcus agalactiae, Escherichia coli, Proteus mirabilis, Neisseria gonorrhoeae, Bacteroides</i> spp. (excluding <i>Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron</i>), <i>Fusobacterium</i> spp., and gram-positive anaerobic cocci (including <i>Peptococcus</i> and <i>Peptostreptococcus</i> spp.).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Cefotetan has no activity against <i>Chlamydia (Chlamydophila) trachomatis</i>. When treating pelvic inflammatory disease, add appropriate antichlamydial coverage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections: </b> Treatment of intra-abdominal infections caused by <i>E. coli, Klebsiella</i> spp. (including <i>K. pneumoniae</i>), <i>Streptococcus</i> spp. (excluding enterococci) and <i>Clostridium</i> spp.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower respiratory tract infections: </b>Treatment of lower respiratory tract infections caused by <i>Streptococcus pneumoniae, S. aureus</i> (penicillinase- and non-penicillinase-producing strains), <i>Haemophilus influenzae</i> (including ampicillin-resistant strains), <i>Klebsiella </i>spp. (including <i>K. pneumoniae</i>), <i>E. coli, P. mirabilis,</i> and <i>Serratia marcescens</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Serious infections: </b> Treatment of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections (often administered with concomitant aminoglycosides).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections: </b> Treatment of skin and skin structure infections due to <i>S. aureus</i> (penicillinase- and non-penicillinase-producing strains), <i>Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus</i> spp. (excluding enterococci), <i>E. coli, K. pneumoniae, Peptococcus niger</i>, <i>Peptostreptococcus</i> spp.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis: </b> Preoperative administration in surgical procedures that are classified as clean contaminated or potentially contaminated (eg, cesarean section, abdominal or vaginal hysterectomy, transurethral surgery, biliary tract surgery, GI surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections: </b> Treatment of urinary tract infections caused by <i>E. coli</i>, <i>Klebsiella</i> spp. (including <i>K. pneumoniae</i>), <i>P. mirabilis </i>and <i>Proteus</i> spp. (which may include the organisms now called <i>Proteus vulgaris, Providencia rettgeri</i>, and <i>Morganella morganii</i>).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49167543\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Pelvic inflammatory disease (PID) in adolescents, intra-abdominal infections (children and adolescents), surgical (perioperative) prophylaxis in children.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147630\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CefoTEtan may be confused with ceFAZolin, cefOXitin, cefTAZidime, Ceftin, cefTRIAXone</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147562\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum transaminases (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, anaphylaxis, eosinophilia, fever, hemolytic anemia, hemorrhage, increased blood urea nitrogen, increased serum creatinine, leukopenia, nausea, nephrotoxicity, phlebitis, prolonged prothrombin time, pruritus, pseudomembranous colitis, skin rash, thrombocythemia, thrombocytopenia, urticaria, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147578\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefotetan, any component of the formulation, or other cephalosporins; previous cephalosporin-associated hemolytic anemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147559\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated INR: May be associated with increased INR and subsequent bleeding, especially in nutritionally deficient patients, prolonged treatment, or patients with cancer, hepatic or renal disease. Monitor coagulation parameters and manage as clinically indicated (eg, administration of phytonadione).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic anemia: May rarely cause hemolytic anemia (including fatalities). Has been associated with a higher risk of hemolytic anemia relative to other cephalosporins (approximately threefold); monitor carefully during use and consider cephalosporin-associated immune anemia in patients who have received cefotetan within 2 to 3 weeks (either as treatment or prophylaxis). Discontinue drug, if applicable, and institute supportive measures as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, may occur. If an allergic reaction occurs, discontinue treatment and institute appropriate supportive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI disease: Use with caution in patients with a history of GI disease, particularly colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298991\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147564\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9222&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CefoTEtan may enhance the adverse/toxic effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbocisteine: CefoTEtan may enhance the adverse/toxic effect of Carbocisteine. Specifically, cefotetan may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147589\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Concurrent use with ethanol may cause a disulfiram-like reaction. Management: Monitor patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147567\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6347590\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Cefotetan crosses the placenta and produces therapeutic concentrations in the amniotic fluid and cord serum. Cefotetan is one of the antibiotics recommended for use with cesarean delivery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147580\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Very small amounts of cefotetan are excreted in human milk. The manufacturer recommends caution when giving cefotetan to a breast-feeding mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147581\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147569\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor renal, hepatic, and hematologic function periodically with prolonged therapy. Monitor prothrombin time in patients at risk of prolongation during cephalosporin therapy (nutritionally-deficient, prolonged treatment, renal or hepatic disease). Monitor for signs and symptoms of hemolytic anemia, including hematologic parameters where appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147558\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147577\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Widely to body tissues and fluids including bile, gallbladder, kidney, skin, tonsils, uterus, sputum, prostatic and peritoneal fluids</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 88%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 3 to 4.6 hours, prolonged in patients with moderately impaired renal function (up to 10 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: 1 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (51% to 81%, as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323048\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefotan Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $47.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $95.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefoTEtan Disodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $23.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $46.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $228.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefoTEtan Disodium-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g 3.58% (1): $18.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g 2.08% (1): $25.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038554\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apacef (BE, FR, LU);</li>\n      <li>Apatef (AU, DE, IT, PT);</li>\n      <li>Ceftenon (AT);</li>\n      <li>Darvilen (DE);</li>\n      <li>Kuptamete (VN);</li>\n      <li>Yamatetan (JP, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases. </i>30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey K, &ldquo;Orbital Cellulitits and Abscess,&rdquo; <i>Roy and Fraunfelder&rsquo;s Current Ocular Therapy</i>, Chapter 325, 6th ed, Roy FH, Fraunfelder FW, and Fraunfelder FT, eds, New York, NY: Saunders, 2007, 601.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(2):187-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/10069359/pubmed\" target=\"_blank\" id=\"10069359\">10069359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin C, Thomachot L, and Albanese J, &ldquo;Clinical Pharmacokinetics of Cefotetan,&rdquo; <i>Clin Pharmacokinet</i>, 1994, 26(4):248-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/8013159/pubmed\" target=\"_blank\" id=\"8013159\">8013159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quayle AA, Russell C, and Hearn B, &ldquo;Organisms Isolated from Severe Odontogenic Soft Tissue Infections: Their Sensitivities to Cefotetan and Seven Other Antibiotics, and Implications for Therapy and Prophylaxis,&rdquo; <i>Br J Oral Maxillofac Surg</i>, 1987, 25(1):34-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/2948542/pubmed\" target=\"_blank\" id=\"2948542\">2948542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>,  2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9222 Version 127.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46216290\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F147623\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F147596\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F147614\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F147597\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F147598\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682538\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147571\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F147555\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F147575\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F147574\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F49167543\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147630\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147562\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147578\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147559\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298991\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147564\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F147589\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147567\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6347590\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F147580\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F147581\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F147569\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147558\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F147577\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323048\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038554\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9222|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefotetan-patient-drug-information\" class=\"drug drug_patient\">Cefotetan: Patient drug information</a></li><li><a href=\"topic.htm?path=cefotetan-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefotetan: Pediatric drug information</a></li></ul></div></div>","javascript":null}